HC Wainwright keeps Buy rating on Oculis with $39 price target
HC Wainwright reiterated its Buy rating on Oculis Holding with a $39 price target, citing biomarker data for its privosegtor drug candidate.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
HC Wainwright & Co. reiterated its Buy rating on Oculis Holding shares with a $39.00 price target. According to TradingView, citing Benzinga, the target implies an upside of 382.1% from the October 22 close of $8.09.
The analyst note highlighted biomarker findings from the Phase 2 ACUITY trial, where privosegtor significantly reduced markers of neuroaxonal injury and reactive astrocytic activation versus placebo, particularly shortly after disease onset. The company is also advancing its PIONEER program for acute optic neuritis and plans an IND filing for acute multiple sclerosis relapses.
The analysts said these steps could further support investor confidence in the stock.
why it matters
This is a single-company story: one broker's rating and price target rarely move the broader market. For Oculis investors, the drug data and the timing of regulatory milestones matter more.
tags
instruments
sources
- HC Wainwright & Co. reiterates Buy rating on Oculis Holding, $39 price target — TradingView, 23 October 2026 at 10:32 UTC
- Oculis Holding Price Target Maintained With a $39.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 23 October 2026 at 10:42 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗